[Etherboot-developers] The fever is getting hot5838
Brought to you by:
marty_connor,
stefanhajnoczi
Menu
▾
▴
[Etherboot-developers] The fever is getting hot5838
|
From: Susan W. <lay...@ma...> - 2002-12-20 06:16:49
|
<html xmlns:v=3D"urn:schemas-microsoft-com:vml" xmlns:o=3D"urn:schemas-microsoft-com:office:office" xmlns:w=3D"urn:schemas-microsoft-com:office:word" xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags" xmlns=3D"http://www.w3.org/TR/REC-html40"> <head> <meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-12= 52"> <meta name=3DProgId content=3DWord.Document> <meta name=3DGenerator content=3D"Microsoft Word 9"> <meta name=3DOriginator content=3D"Microsoft Word 9"> <link rel=3DFile-List href=3D"./12-18-02%20RJVM%20edited%20version%202%20jrs-stacy%20optin_files= /filelist.xml"> <link rel=3DEdit-Time-Data href=3D"./12-18-02%20RJVM%20edited%20version%202%20jrs-stacy%20optin_files= /editdata.mso"> <!--[if !mso]> <style> v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} shape {behavior:url(#default#VML);} </style> <![endif]--> <title>This message has been sent to you in compliance with our strict ant= i </title> <!--[if gte mso 9]><xml> <o:DocumentProperties> <o:Author>Melanie Marco</o:Author> <o:Template>Normal</o:Template> <o:LastAuthor>Paul W</o:LastAuthor> <o:Revision>2</o:Revision> <o:TotalTime>55</o:TotalTime> <o:Created>2002-12-19T18:35:00Z</o:Created> <o:LastSaved>2002-12-19T18:35:00Z</o:LastSaved> <o:Pages>4</o:Pages> <o:Words>1427</o:Words> <o:Characters>8136</o:Characters> <o:Lines>67</o:Lines> <o:Paragraphs>16</o:Paragraphs> <o:CharactersWithSpaces>9991</o:CharactersWithSpaces> <o:Version>9.2720</o:Version> </o:DocumentProperties> </xml><![endif]--><!--[if gte mso 9]><xml> <w:WordDocument> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> <w:SpellingState>Clean</w:SpellingState> <w:GrammarState>Clean</w:GrammarState> </w:WordDocument> </xml><![endif]--> <style> <!-- span.SPELLE {mso-spl-e:yes;} span.GRAME {mso-gram-e:yes;} /* Font Definitions */ @font-face {font-family:Tahoma; panose-1:2 11 6 4 3 5 4 4 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:553679495 -2147483648 8 0 66047 0;} @font-face {font-family:Verdana; panose-1:2 11 6 4 3 5 4 4 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:536871559 0 0 0 415 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-parent:""; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman"; mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink {color:blue; text-decoration:underline; text-underline:single;} a:visited, span.MsoHyperlinkFollowed {color:blue; text-decoration:underline; text-underline:single;} p {margin-right:0in; mso-margin-top-alt:auto; mso-margin-bottom-alt:auto; margin-left:0in; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman"; mso-fareast-font-family:"Times New Roman";} @page Section1 {size:8.5in 11.0in; margin:1.0in 1.25in 1.0in 1.25in; mso-header-margin:.5in; mso-footer-margin:.5in; mso-paper-source:0;} div.Section1 {page:Section1;} /* List Definitions */ @list l0 {mso-list-id:18090482; mso-list-template-ids:1595051474;} @list l0:level1 {mso-level-number-format:bullet; mso-level-text:\F0B7; mso-level-tab-stop:.5in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:Symbol;} ol {margin-bottom:0in;} ul {margin-bottom:0in;} --> </style> <o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags= " name=3D"State"/><o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-co= m:office:smarttags" name=3D"City"/><o:SmartTagType namespaceuri=3D"urn:sch= emas-microsoft-com:office:smarttags" name=3D"country-region"/><o:SmartTagT= ype namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags" name=3D"pl= ace"/><o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:sma= rttags" name=3D"PlaceName"/><o:SmartTagType namespaceuri=3D"urn:schemas-mi= crosoft-com:office:smarttags" name=3D"PlaceType"/> <meta http-equiv=3DContent-Language content=3Den-us> </head> <body lang=3DEN-US link=3Dblue vlink=3Dblue style=3D'tab-interval:.5in'> <div class=3DSection1> <div id=3DmessageBody> <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'> <o:p= ></o:p></p> <div align=3Dcenter> <table border=3D1 cellspacing=3D0 cellpadding=3D0 width=3D"63%" style=3D'w= idth:63.1%; mso-cellspacing:0in;margin-left:-.4pt;border:outset #89BE65 1.5pt;mso-pad= ding-alt: 5.25pt 5.25pt 5.25pt 5.25pt' height=3D71 bordercolordark=3D"#000000" bordercolorlight=3D"#000000"> <tr style=3D'height:329.25pt;mso-yfti-irow:0'> <td width=3D"100%" valign=3Dtop style=3D'width:100.0%;border:inset #89BE= 65 .75pt; padding:5.25pt 5.25pt 5.25pt 5.25pt;height:329.25pt'> <div align=3Dcenter> <table border=3D1 cellpadding=3D0 width=3D"75%" style=3D'width:75.0%;mso= -cellspacing: 1.5pt;margin-left:.5in;mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-yfti-iro= w:0'> <tr style=3D'mso-yfti-irow:0;mso-yfti-lastrow:yes'> <td style=3D'background:#003300;padding:.75pt .75pt .75pt .75pt'> <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b><i>= <span style=3D'font-size:24.0pt;color:white'>STOCK ALERT</span></i></b></p> </td> </tr> </table> </div> <p align=3Dcenter style=3D'margin-right:.5in;margin-left:.5in;text-align= :center'><b><span style=3D'font-size:10.0pt;font-family:Verdana'> </span></b><b><i><u= ><span style=3D'font-family:Verdana;color:#0000A0'><a href=3D"http://biz.yahoo.com/n/r/rjvn.ob.html">RJV Networks, Inc. (OTC B= B: RJNV)</a></span></u></i></b></p> <p style=3D'margin-top:0in;margin-right:.5in;margin-bottom:0in;margin-le= ft: .5in;margin-bottom:.0001pt'><b><i><span style=3D'font-family:Verdana'>TA= RGET Price $4 -to- $6 in January 2003<span style=3D'color:#0000A0'><br> </span></span></i></b></p> <p style=3D'margin-top:0in;margin-right:.5in;margin-bottom:0in;margin-le= ft: .5in;margin-bottom:.0001pt'><b><span style=3D'font-family:Verdana;color:= #0000A0'>Tonight:</span></b><b><span style=3D'font-family:Verdana;color:#3A8357'> </span></b><b><span style=3D'font-family:Verdana;color:#0000A0'> </span></b><b><span style=3D'font-size:10.0pt;font-family:Verdana;color:#5F5F5F'>RJNV holds exclusive licenses to state-of-the-art bio-technology developed at <st1:= place><st1:PlaceType>University</st1:PlaceType> of <st1:PlaceName>Michigan</st1:PlaceName></st1:place> and the Cancer Co= ntrol Agency of B.C. that experts are using to develop therapies believed to b= e capable of treating most cancers. </span></b></p> <p style=3D'margin-right:.5in;margin-left:.5in'><b><span style=3D'font-s= ize:10.0pt; font-family:Verdana;color:#5F5F5F'>Through an acquisition of BioKinetix Research, Inc. (currently underway), RJVN is rapidly completing the deve= lopment of a therapy for cancer that will make a lasting impression on the multibillion dollar bio-tech industry. Read more about this exciting up = and comer below.</span></b> </p> <div class=3DMsoNormal align=3Dcenter style=3D'margin-top:0in;margin-rig= ht:.5in; margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:cent= er'> <hr size=3D2 width=3D"100%" align=3Dcenter> </div> <div align=3Dcenter> <table border=3D1 cellspacing=3D0 cellpadding=3D0 width=3D"69%" style=3D= 'width:69.0%; mso-cellspacing:0in;margin-left:.5in;border:outset black .75pt;mso-padd= ing-alt: 3.75pt 3.75pt 3.75pt 3.75pt' height=3D86 bordercolordark=3D"#000000" bordercolorlight=3D"#000000"> <tr style=3D'height:58.5pt;mso-yfti-irow:0;mso-yfti-lastrow:yes'> <td width=3D"100%" style=3D'width:100.0%;border:inset black .75pt;back= ground: #F0F0F0;padding:3.75pt 3.75pt 3.75pt 3.75pt;height:58.5pt'> <p class=3DMsoNormal><b><span style=3D'font-size:10.0pt;font-family:Ve= rdana; color:#3A8357'>Company Name </span></b><b><span style=3D'font-siz= e:10.0pt; font-family:Verdana'> <= span style=3D'color:#5F5F5F'> </span><span style=3D'color:#022051'>RJV Netw= orks, Inc.</span><br> <span style=3D'color:#3A8357'>Symbol </span> &nb= sp;<span style=3D'color:#3A8357'> &nbs= p; </span><span style=3D'color:= #5F5F5F'> </span><span style=3D'color:#022051'>RJVN</span><span style=3D'color:#= 3A8357'><br> Current Price &nb= sp; </span><span style=3D'color:#5F5F5F'> </span><span style=3D'color:#02205= 1'> $0.26</span><span style=3D'color:#3A8357'><br> 52 Week High</span><span style=3D'color:#5F5F5F'> </span><span style=3D'color:black'> </span><span style=3D'co= lor:#3A8357'> </span><span style=3D'color:#022051'>$2.10</span><span style=3D'color:= #3A8357'><br> 52 Week Low &= nbsp; </span><span style=3D'color:#022051'>$0.26</span></span></b></p> <p><b><span style=3D'font-family:Verdana;color:#022051'>Target $4 -to- $6 Q1/2003</span></b></p> </td> </tr> </table> </div> <p style=3D'margin-right:.5in;margin-left:.5in'><b><span style=3D'font-f= amily: Verdana;color:#0000A0'>Investment Highlights</span></b></p> <p class=3DMsoNormal style=3D'margin-right:.5in;mso-margin-top-alt:auto; mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list= : l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>= =FFFFFFB7<span style=3D'font:7.0pt "Times New Roman"'> &nb= sp; </span></span><![endif]><span style=3D'font-size:10.0pt;font-family:Verd= ana; color:#0000A0'>RJVN </span><span style=3D'font-size:10.0pt;font-family:V= erdana'>projects<b> it will be able to treat most cancers with its combined targeted therapy treatment which is based upon an astounding discovery by a molecular biologist at the <st1:place><st1:PlaceType>Univ.</st1:PlaceType> of <st1= :PlaceName>Michigan</st1:PlaceName></st1:place> - The causal link to breast and most other malignancies and cancers in t= he protein Mammastatin.</b></span></p> <p class=3DMsoNormal style=3D'margin-right:.5in;mso-margin-top-alt:auto; mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list= : l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>= =FFFFFFB7<span style=3D'font:7.0pt "Times New Roman"'> &nb= sp; </span></span><![endif]> </p> <p class=3DMsoNormal style=3D'margin-right:.5in;mso-margin-top-alt:auto; mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list= : l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>= =FFFFFFB7<span style=3D'font:7.0pt "Times New Roman"'> &nb= sp; </span></span><![endif]><span style=3D'font-size:10.0pt;font-family:Verd= ana'>RJVN has developed a series of cancer treatment therapies which utilize pan-c= ancer market antibodies. Antibody therapies do not create chemical toxicity an= d, as such, are fast tracked through the regulatory approval process. Usi= ng this approach, RJVN is targeted to enter testing for its products in six months.</span></p> <p class=3DMsoNormal style=3D'margin-right:.5in;mso-margin-top-alt:auto; mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list= : l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>= =FFFFFFB7<span style=3D'font:7.0pt "Times New Roman"'> &nb= sp; </span></span><![endif]> </p> <p class=3DMsoNormal style=3D'margin-right:.5in;mso-margin-top-alt:auto; mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list= : l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>= =FFFFFFB7<span style=3D'font:7.0pt "Times New Roman"'> &nb= sp; </span></span><![endif]><b><span style=3D'font-size:10.0pt;font-family:V= erdana; color:#306D48'>RJVN's</span></b><span style=3D'font-size:10.0pt;font-fam= ily: Verdana'> combination of two leading, well known technologies previously announced by BioCurex and InNexus Corp along with RJVN's key MAb protein replicating technology has allowed the Company to create a series of pat= ented therapeutic products that many molecular biologists believe will <b><i>t= reat most cancers.</i></b></span></p> <p class=3DMsoNormal style=3D'margin-right:.5in;mso-margin-top-alt:auto; mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list= : l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>= =FFFFFFB7<span style=3D'font:7.0pt "Times New Roman"'> &nb= sp; </span></span><![endif]> </p> <p class=3DMsoNormal style=3D'margin-right:.5in;mso-margin-top-alt:auto; mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list= : l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>= =FFFFFFB7<span style=3D'font:7.0pt "Times New Roman"'> &nb= sp; </span></span><![endif]><b><span style=3D'font-size:10.0pt;font-family:V= erdana; color:#306D48'>RJVN</span></b><span style=3D'font-size:10.0pt;font-famil= y:Verdana; color:#306D48'>'s R&D and Management are led by Dr. John Todd, Dr. Charles Morgan (a world renowned molecular biologist and 5 other industr= y leading Dr's all with several years experience in bio-tech development.&= nbsp; </span><o:p></o:p></p> <div align=3Dcenter> <table border=3D1 cellspacing=3D0 cellpadding=3D0 width=3D"92%" bgcolor=3D= red style=3D'width:92.0%;mso-cellspacing:0in;background:red;border:outset w= hite 1.5pt; mso-padding-alt:5.25pt 5.25pt 5.25pt 5.25pt' bordercolordark=3D"#ffffff= " bordercolorlight=3D"#ffffff"> <tr style=3D'mso-yfti-irow:0;mso-yfti-lastrow:yes'> <td width=3D"100%" style=3D'width:100.0%;border:inset white .75pt;back= ground: #0000A0;padding:5.25pt 5.25pt 5.25pt 5.25pt'> <p align=3Dcenter style=3D'text-align:center'><b><span style=3D'font-s= ize:13.5pt; font-family:Verdana;color:#EEEEEE'>About the Company</span></b></p> </td> </tr> </table> </div> <p style=3D'margin-right:.5in;margin-left:.5in'><span style=3D'font-size= :10.0pt; font-family:Verdana'>RJVN (through BioKinetix Research, Inc.) was formed after Dr. John Todd, a very well known and respected oncological surgeon= from BC, approached us with the story of an astounding discovery that had bee= n made by molecular biologists at the University of Michigan. This discovery was believed to be the causal link to breast cancer, the link = is a medium sized (53KD) protein called Mammastatin. The evidence is tha= t Mammastatin is the agent that, when present, prevents the development an= d growth of malignant breast tumors. Mammastatin is freely expressed by th= e epithelial cells in the breast and as such acts as a natural contra-agen= t to malignant development. Women who develop breast cancer have NO or extremely low levels of Mammastatin in their system. After testing hundreds of women, no woman with normal Mammastatin levels has developed breast cancer.</span></p> <p style=3D'margin-right:.5in;margin-left:.5in'><span style=3D'font-size= :10.0pt; font-family:Verdana'>Dr. John Todd in conjunction with the Cancer Contro= l Agency of B.C. conducted compassionate trials on several terminally ill patients (authorized by Health <st1:country-region><st1:place>Canada</st= 1:place></st1:country-region>) with a Mammastatin replacement program the results of which thoroughly convinced Dr. Todd of the direct link. The challenge existed from t= he fact that proteins are extremely difficult to sequence (replicate). = ; Mammastatin has over 400 amino-acids in its chain, and, even if successf= ul in sequencing, the synthetic replication is even more difficult. Fina= lly the delivery of a protein, natural or synthetic, will now have to face t= he natural breakdown of the chain as it circulates through the body.</span></p> <p style=3D'margin-right:.5in;margin-left:.5in'><span style=3D'font-size= :10.0pt; font-family:Verdana'>Dr. Charles Morgan is a world-renowned molecular biologist who has proposed an alternative approach to this problem. = ; He is convinced, and several well known molecular biologists agree with him= , that he can mimic the active component of the Mammastatin protein throug= h the production of an anti-idiotypic monoclonal antibody (MAb). These MA= bs are stable, target specific and will in all measure act like the native Mammastatin. To dramatically enhance the bio-activity of these anti-idiotypic monoclonal antibodies, RJNV will create Superantibodies through the use of InNexus' Super Antibody platform technology (see news= for <a href=3D"http://biz.yahoo.com/n/b/bocx.ob.html">OTC BB: BOCX</a> about th= is technology). This technology allows the cross linking of antibodies to b= oost their potency and resiliency.</span></p> <p style=3D'margin-right:.5in;margin-left:.5in'><span style=3D'font-size= :10.0pt; font-family:Verdana'>As a result of the scientific approach implemented = by RJNV's BioKinetix (acquisition underway), the company has negotiated a license from BioCurex <a href=3D"http://biz.yahoo.com/n/b/bocx.ob.html">= OTC BB: BOCX</a> to develop therapeutic products based on their pan-cancer marke= r antibodies. The combination of these two technologies gives RJVN th= e potential to create a series of therapeutic products that will treat mos= t cancers.<o:p></o:p></span></p> <p style=3D'margin-right:.5in;margin-left:.5in'><span style=3D'font-size= :10.0pt; font-family:Verdana'>Antibody therapies do not create chemical toxicity = and, as such, are fast tracked through the regulatory approval process. = Using this approach, RJVN is targeted to enter testing for its products in six months.</span><o:p></o:p></p> <table border=3D1 cellspacing=3D1 cellpadding=3D0 width=3D"90%" style=3D= 'width:90.0%; mso-cellspacing:.7pt;margin-left:.5in;border:none;mso-padding-alt:0in 5= 4pt 0in 5.4pt' height=3D48> <tr style=3D'height:.5in;mso-yfti-irow:0;mso-yfti-lastrow:yes'> <td width=3D"100%" style=3D'width:100.0%;border:none;background:#0000A= 0; padding:.75pt .75pt .75pt .75pt;height:.5in'> <p align=3Dcenter style=3D'text-align:center'><b><span style=3D'font-s= ize:13.5pt; font-family:Verdana;color:#EEEEEE'>Industry Potential</span></b></p> </td> </tr> </table> <p style=3D'margin-right:.5in;margin-left:.5in'><b><span style=3D'font-s= ize:10.0pt; font-family:Verdana'>The potential market for RJVN's cancer treatment therapies far outstrips any reasonable estimate to be made at this time. As the Company implements its technology upon entering the m= arket test phase, we expect a large bio-tech or pharmaceutical mfr. to acquire= the Company for several hundred million.<o:p></o:p></span></b></p> <p style=3D'margin-right:.5in;margin-left:.5in'><b><span style=3D'font-s= ize:10.0pt; font-family:Verdana'>Due to the Companies ability to fast track, beginni= ng clinical trials of its revolutionary cancer treatment in early 2003E, exposure of its initial success will spread quickly. </span></b><o= :p></o:p></p> <div align=3Dcenter> <table border=3D1 cellspacing=3D0 cellpadding=3D0 width=3D"88%" bgcolor=3D= "#022051" style=3D'width:88.0%;mso-cellspacing:0in;margin-left:.5in;background:#0= 22051; border:none;mso-padding-alt:0in 5.4pt 0in 5.4pt' height=3D44> <tr style=3D'height:31.5pt;mso-yfti-irow:0;mso-yfti-lastrow:yes'> <td width=3D"100%" style=3D'width:100.0%;border:none;background:#0000A= 0; padding:.75pt .75pt .75pt .75pt;height:31.5pt'> <p align=3Dcenter style=3D'text-align:center'><b><span style=3D'font-s= ize:13.5pt; font-family:Verdana;color:white'>Conclusion</span></b></p> </td> </tr> </table> </div> <p style=3D'margin-right:.5in;margin-left:.5in'><b><span style=3D'font-s= ize:10.0pt; font-family:Verdana'>The Company will be participating in a road-show in January and February of 2003, meeting with several institutional brokera= ge houses in <st1:place><st1:City>San Francisco</st1:City>, <st1:State>New = York</st1:State></st1:place>, and other major metro areas to showcase their technology. We expec= t many pension fund managers to begin positioning the stock in their portf= olios sometime in Q1/2003 and Q2/2003.</span></b></p> <p style=3D'margin-right:.5in;margin-left:.5in'><b><span style=3D'font-s= ize:10.0pt; font-family:Verdana'>The stock is highly undervalued currently due to th= e fact that there has been no P/R done on the Company. Mass direct m= ail, investment club profiles and other P/R related activities are beginning = with the issuance of this newsletter. We expect the stock to appreciate significantly over the next 20-trading days.</span></b></p> <p style=3D'margin-right:.5in;margin-left:.5in'><b><span style=3D'font-s= ize:10.0pt; font-family:Verdana'>TARGET Price $4 -to- $6 in January 2003</span></b><= /p> <p style=3D'margin-right:.5in;margin-left:.5in'> </p> </td> </tr> <tr style=3D'height:105.15pt;mso-yfti-irow:1'> <td width=3D"100%" valign=3Dtop style=3D'width:100.0%;border:inset #89BE= 65 .75pt; padding:5.25pt 5.25pt 5.25pt 5.25pt;height:105.15pt'> <p class=3DMsoNormal><span style=3D'font-size:7.5pt;font-family:Verdana'= >******************* </span><b style=3D'mso-bidi-font-weight:normal'><span style=3D'font-size= :10.0pt; font-family:Verdana'>Special Offer</span></b><span style=3D'font-size:7.= 5pt; font-family:Verdana'> *******************<o:p></o:p></span></p> <p class=3DMsoNormal><span style=3D'font-size:10.0pt;font-family:Verdana= '>If you would like to be included in our mailing list, you will<o:p></o:p></span= ></p> <p class=3DMsoNormal><span style=3D'font-size:10.0pt;font-family:Verdana= '>receive a 10 day free trial to a web site with real-time<o:p></o:p></span></p> <p class=3DMsoNormal><span style=3D'font-size:10.0pt;font-family:Verdana= '>Level II quotes, research reports from major providers, analyst upgrades/downg= rade info, Bulletin Board Promotion/Syndication Calendar (1st of its kind), a= nd access to our trading chat rooms<o:p></o:p></span></p> <p class=3DMsoNormal><span style=3D'font-size:10.0pt;font-family:Verdana= '>and to several message boards with real live professionals. Just<o:p></o:p></sp= an></p> <p class=3DMsoNormal><span style=3D'font-size:10.0pt;font-family:Verdana= '>click on this link: <a href=3D"mailto:st...@ex...?subject=3DOpt-in">Opt= -in</a> to send us an email, and you will be immediately added. <o:p></o:p></spa= n></p> <p class=3DMsoNormal><span style=3D'font-size:7.5pt;font-family:Verdana'= > <o:p></o:p></span></p> </td> </tr> <tr style=3D'height:210.0pt;mso-yfti-irow:2;mso-yfti-lastrow:yes'> <td width=3D"100%" valign=3Dtop style=3D'width:100.0%;border:inset #89BE= 65 .75pt; padding:5.25pt 5.25pt 5.25pt 5.25pt;height:210.0pt'> <p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'> </b>= <b style=3D'mso-bidi-font-weight:normal'><span style=3D'font-size:7.5pt;fon= t-family: Verdana'>Disclaimer</span></b><span style=3D'font-size:7.5pt;font-family= :Verdana'> <br> Information within this email contains "forward looking statements&= quot; within the meaning of Section 27A of the Securities Act of 1933 and Sect= ion 21B of the Securities Exchange Act of 1934. Any statements that express = or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forwa= rd looking statements."<br> <br> Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or even= ts to differ materially from those presently anticipated. Forward looking stat= ements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this emai= l pertaining to investing, stocks, securities must be understood as inform= ation provided and not investment advice. Emerging Equity Alert advises all re= aders and subscribers to seek advice from a registered professional secur= ities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed = as any kind of investment advice.<br> <br> In compliance with the Securities Act of 1933, Section17(b), Emerging St= ock Alert discloses the receipt of 125,000 unrestricted shares of RJVN from = a third party for the publication of this report. Be aware of an inherent conflict of interest resulting from such compensation due to our intent = to profit from the liquidation of these shares. Shares may be sold at= any time, even after positive statements have been made regarding the above company. All factual information in this report was gathered = from public sources, including but not limited to SEC filings, Company Press = Releases, and Market Guide. Emerging Equity Alert believes this informa= tion to be reliable but can make no guarantee as to its accuracy or completen= ess. Use of the material within this email constitutes your acceptance of the= se terms.</span></p> </td> </tr> </table> </div> <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span style=3D'display:none;mso-hide:all'> <o:p></o:p></span></p> <p class=3DMsoNormal> <o:p></o:p></p> </div> <table border=3D1 cellspacing=3D0 cellpadding=3D0 width=3D333 style=3D'wid= th:249.75pt; margin-left:152.55pt;border-collapse:collapse;border:none;mso-border-alt:= solid windowtext .5pt; mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-yfti-tbllook:191;mso-border-insid= eh:.5pt solid windowtext; mso-border-insidev:.5pt solid windowtext'> <tr style=3D'height:56.95pt;mso-yfti-irow:0;mso-yfti-lastrow:yes'> <td valign=3Dtop style=3D'border:solid windowtext .5pt;padding:0in 5.4pt= 0in 5.4pt; height:56.95pt'> <p class=3DMsoNormal> <meta http-equiv=3Dpragma content=3Dno-cache> <b style=3D'mso-bidi-font-weight:normal'><span style=3D'font-size:10.0pt= ; font-family:Verdana'> <meta http-equiv=3Dcache-control content=3Dno-cache> <meta http-equiv=3Dexpires content=3D"Sun, 21 Mar 1999 06:05:29 GMT"> ****** Advertising Disclaimer ******<o:p></o:p></span></b></p> <p class=3DMsoNormal><span style=3D'font-size:10.0pt;font-family:Verdana= '>We have received monetary payment for this mailing service We hold no stocks and= hold no personal interest in this company.</span></p> </td> </tr> </table> <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'> </p> <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'> </p> <p class=3DMsoNormal> </p> <p class=3DMsoNormal><span style=3D'font-size:7.5pt;font-family:Arial;colo= r:black'>This message has been sent to you in compliance with our strict anti-abuse regulations. We will continue to bring you valuable offers on the products= and services that interest you most. If you do not wish to receive further mailings, please click below. You may then rest-assured that you will never receive another email from us again. </span><b><span style=3D'font-size:7.5pt;font-family:Tahoma;color:black'>We respect all re= moval requests.</span></b><span style=3D'font-size:7.5pt;font-family:Arial;color= :black'> To be immediately removed from our mailing lists just click on this link <= a href=3D"mailto:kr...@ya...?subject=3DUnsubscribe%20me%20please">UNSUBS= CRIBE ME PLEASE</a> . This message is an advertisement. Copyright 2000, 2001, 2002 = all rights reserved. </span></p> </div> </body> </html> |
